Clinical laboratory最新文献

Sparganum-Induced Eosinophilic Pleural Effusion: a Case Report Emphasizing Laboratory Diagnostic Strategies. spargins诱导的嗜酸性胸腔积液：一个强调实验室诊断策略的病例报告。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250358

Chunxiao He, Qing Wang, Xiuping Xu

{"title":"Sparganum-Induced Eosinophilic Pleural Effusion: a Case Report Emphasizing Laboratory Diagnostic Strategies.","authors":"Chunxiao He, Qing Wang, Xiuping Xu","doi":"10.7754/Clin.Lab.2025.250358","DOIUrl":"10.7754/Clin.Lab.2025.250358","url":null,"abstract":"Background: Eosinophilic pleural effusion (EPE), characterized by atypical symptoms and rarity, is easily over-looked and misdiagnosed.Methods: The patient underwent comprehensive routine laboratory tests including blood analysis and pleural effusion examination, along with B-ultrasound and computed tomography (CT) imaging. Based on combined evaluation of the epidemiological history, serum-specific parasite antibody detection and targeted Next-Generation Sequencing were performed on the clinical specimens.Results: The blood routine and pleural fluid routine of the patients suggested that the eosinophils were significantly increased. The serum-specific parasite antibody detection showed positive sparganosis antibody. Based on the diagnosis of sparganosis for this patient, he was treated with praziquantel and pleural effusion drainage, and the symptoms improved significantly.Conclusions: The etiological diagnosis of EPE is challenging and requires a comprehensive evaluation of clinical symptoms, epidemiological history, and laboratory test results. When parasitic pleural effusion is strongly suspected, tests such as serum-specific parasite antibody detection can aid in confirming the diagnosis.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Breath Alcohol Screening Test Results with Alcohol Concentration in Venous Blood in Drivers During Traffic Inspection. 交通检查中驾驶员呼吸酒精筛查结果与静脉血酒精浓度的比较

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250110

Sibel Kulaksizoğlu, Ökkeş Zortuk, Fatih Selvi, Engin Karsli

{"title":"Comparison of Breath Alcohol Screening Test Results with Alcohol Concentration in Venous Blood in Drivers During Traffic Inspection.","authors":"Sibel Kulaksizoğlu, Ökkeş Zortuk, Fatih Selvi, Engin Karsli","doi":"10.7754/Clin.Lab.2025.250110","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250110","url":null,"abstract":"Background: Alcohol has been demonstrated to impair an individual's cognitive and motor abilities, resulting in a range of adverse consequences. Moreover, the probability of vehicular accidents is elevated in the aftermath of alcohol-impaired driving. The objective of this study was to evaluate the concordance between alcohol breath tests and blood alcohol tests used to determine alcohol levels, as well as the effect of time.Methods: This study was conducted retrospectively in a tertiary education and research hospital. The objective of this study was to analyze the relationship between the results of alcohol breath tests performed by traffic police officers in the field and the ethanol levels detected in the blood after hospital admission.Results: The present study encompassed 500 participants, with a mean age of 35.63 years (± 9.92) and a female percentage of 13.6%. The mean alcohol breath test result was 0.64 ± 0.35 per mill, while the mean blood alcohol test result was 0.40 ± 0.32. A comparison of the two sets of results revealed a deviation of 0.12 per mill between 0 and 1 hour without correction, which was statistically significant (p = 0.001). Additionally, a deviation of 0.202 per mill was observed between 0 and 2 hours (p = 0.001), and a deviation of 0.04 per mill was detected after correction according to time (p = 0.0015).Conclusions: The alcohol breath test (ABT) exhibits a correspondence with the blood ethanol test (BET), thereby permitting the safe use of the ABT performed at the scene.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary Acute Myeloid Leukemia Following Chemotherapy for Angioimmunoblastic T-Cell Lymphoma. 血管免疫母细胞t细胞淋巴瘤化疗后继发急性髓系白血病。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250232

Shenghong Lin, Jing Xu

{"title":"Secondary Acute Myeloid Leukemia Following Chemotherapy for Angioimmunoblastic T-Cell Lymphoma.","authors":"Shenghong Lin, Jing Xu","doi":"10.7754/Clin.Lab.2025.250232","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250232","url":null,"abstract":"Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of peripheral T-cell lymphoma, accounting for 1 - 2% of non-Hodgkin lymphomas. Diagnosis is challenging, and there is no established standard first-line treatment. This case report highlights a rare progression from AITL to therapy-related acute myeloid leukemia (AML-pCT) following cytotoxic chemotherapy.Methods: A 61-year-old male presented with fever and a painless right submandibular mass. Initial biopsy and immunohistochemistry confirmed AITL. The patient underwent multiple cycles of chemotherapy, including cyclophosphamide, dexamethasone, bortezomib, and etoposide. Post-treatment, the patient developed severe pancytopenia and was later diagnosed with AML-pCT based on bone marrow examination, flow cytometry, and molecular genetic testing.Results: The patient's initial treatment for AITL included B-CVP and bortezomib-based regimens. Despite initial response, the patient developed AML-pCT, characterized by elevated white blood cells, peripheral blasts, and bone marrow findings of 49.6% blasts. Molecular analysis revealed mutations in FLT3, DNMT3A, TET2, and NPM1. The progression to AML-pCT was attributed to prior cytotoxic therapy, particularly alkylating agents and topoisomerase II inhibitors.Conclusions: This case underscores the rare but significant risk of AML-pCT following cytotoxic chemotherapy for AITL. The presence of specific genetic mutations further supports the diagnosis of therapy-related AML. Clin-icians should be vigilant for such complications in patients receiving intensive chemotherapy, particularly those with underlying hematologic malignancies. Early recognition and tailored management are crucial for improving outcomes in these complex cases.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latent Polycythemia Vera and Chronic Kidney Disease-Associated Erythrocytosis. 潜伏性真性红细胞增多症和慢性肾病相关性红细胞增多症。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250255

Stephen E Langabeer

引用次数: 0

Diagnostic and Prognostic Ability of Serum miR-411-3p in Patients with Acute Myeloid Leukemia. 血清miR-411-3p在急性髓性白血病患者中的诊断和预后能力

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250149

Jun Chen, Mei-Rong Xu, Jin-Bei Yuan, Dong-Ping Liang

引用次数: 0

A Case Report of False Elevation of CA19-9 and Several Treatment Measures. CA19-9假升高1例及治疗措施。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250211

Yaner Qian, Hongkun Xu, Lihong Zhang

引用次数: 0

Free Light Chain Multiple Myeloma: Atypical Appearance on Serum Immunofixation. 游离轻链多发性骨髓瘤：血清免疫固定表现不典型。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250213

N El Aboudi, Y Ourahma, A Biaz, S El M Idrissi, A Dami, S Bouhsain

{"title":"Free Light Chain Multiple Myeloma: Atypical Appearance on Serum Immunofixation.","authors":"N El Aboudi, Y Ourahma, A Biaz, S El M Idrissi, A Dami, S Bouhsain","doi":"10.7754/Clin.Lab.2025.250213","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250213","url":null,"abstract":"Background: Light chain multiple myeloma (LCMM) is a malignant hematological disease characterized by bone marrow infiltration by tumor plasma cells and the secretion of monoclonal free light chains (κ or λ). It is often di-agnosed through hypogammaglobulinemia detected by serum protein electrophoresis, followed by immunotyping showing a monoclonal band in free light chains. However, the structure of monoclonal light chains can sometimes complicate laboratory findings.Methods: The case studied involves a 52-year-old female patient hospitalized for diffuse bone pain and hypercalcemia. Capillary serum protein electrophoresis revealed hypogammaglobulinemia, leading to serum immunofixation (IFE).Results: IFE showed a wide additional band in κ light chains, with no correspondence to the heavy chain antisera (GAM, D, and E), but similar reactivity with the anti-κ light chain, creating an interpretive challenge. The free light chain assay revealed a very high κ/λ ratio (1,068). Bone marrow examination showed 85% plasma cell infiltration, confirming the diagnosis of LCMM.Conclusions: This case highlights the diagnostic challenges encountered in certain cases of light chain multiple myeloma and underscores the importance of a multimarker approach combining serum protein electrophoresis, serum immunofixation, and free light chain assays.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laboratory Measurement of Rivaroxaban in Patient with Cancer-Associated Thromboembolism; Focus on Initial Rivaroxaban Therapy. 利伐沙班在癌症相关性血栓栓塞患者中的实验室检测关注利伐沙班的初始治疗。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.241230

Jung-Hyun Yoon, Eun-Ha Koh, Hyoshim Shin, Haa-Na Song, Sungwoo Park

{"title":"Laboratory Measurement of Rivaroxaban in Patient with Cancer-Associated Thromboembolism; Focus on Initial Rivaroxaban Therapy.","authors":"Jung-Hyun Yoon, Eun-Ha Koh, Hyoshim Shin, Haa-Na Song, Sungwoo Park","doi":"10.7754/Clin.Lab.2025.241230","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.241230","url":null,"abstract":"Background: Data on the levels of rivaroxaban-specific anti-factor Xa activity (AFXaA) within three weeks of starting high-dose rivaroxaban therapy in patients with cancer-associated thromboembolism (CAT) is limited. This study aimed to determine initial levels of rivaroxaban-specific AFXaA in patients with CAT to assist with drug monitoring.Methods: This study included a total of 33 patients from December 2017 through January 2019. The levels of specific AFXaA, as well as prothrombin time (PT) and activated partial thromboplastin time (aPTT), were measured 3 hours after rivaroxaban administration for peak levels, and immediately before rivaroxaban administration, following 3 days of rivaroxaban therapy, for trough levels. We also reviewed complications such as major bleeding of patients treated with rivaroxaban.Results: The median levels of specific AFXaA at trough and peak times were 120.7 and 347.2 ng/mL, respectively. The PT showed a positive correlation with AFXaA activity at both peak and trough levels (trough R = 0.92, peak R = 0.8, p < 0.05). However, aPTT was only weakly correlated with rivaroxaban-specific AFXaA (trough R = 0.39, peak R = 0.37). The levels of specific AFXaA were similar in the event group (venous thromboembolism recurrent, major bleeding, or minor bleeding) and the event-free group. The lowest trough level of AFXaA was present in the relapse group, and the highest level was present in the minor bleeding group (p = 0.39).Conclusions: This study is the first report to determine the trough and peak levels of AFXaA within three weeks of starting high-dose rivaroxaban therapy in patients with CAT in Korea.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma Cell Myeloma Mimicking Bone Marrow Metastasis in a Postpneumonectomy Patient with Lung Cancer. 肺切除术后肺癌患者的浆细胞骨髓瘤模拟骨髓转移。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250216

Haiyang Wang, Fang Long, Ting Li, Jiulian Yuan

引用次数: 0

The Preanalytical Error Rates of Ankara Bilkent City Hospital Central Laboratory. 安卡拉比尔肯特市医院中心实验室分析前错误率。

IF 0.6 4区医学

Clinical laboratory Pub Date : 2025-09-01 DOI: 10.7754/Clin.Lab.2025.250248

Zeliha Kocaismail, Esra Yıldırım Demirçin, Esra Fırat Oğuz

{"title":"The Preanalytical Error Rates of Ankara Bilkent City Hospital Central Laboratory.","authors":"Zeliha Kocaismail, Esra Yıldırım Demirçin, Esra Fırat Oğuz","doi":"10.7754/Clin.Lab.2025.250248","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250248","url":null,"abstract":"Background: Clinical laboratories have a crucial role in the diagnosis, monitoring, and treatment of diseases. The total testing procedure is significantly affected by the preanalytical factors. In this study, we aimed to assess pre-analytical errors to ensure high-quality laboratory performance.Methods: A one-year retrospective data analysis from the Laboratory Information System was conducted, focusing on the sample rejections for the year 2023 from the central laboratory of our hospital. The data is evaluated based on the samples sent from various departments and by the analytic groups studied from these samples.Results: The total number of samples admitted to the central laboratory of the Ankara Bilkent City Hospital were 2,647,527 in year 2023. Out of this total number, 35,024 samples (1.32%) were rejected. Among these rejections, 29,699 samples (84.8%) were rejected due to preanalytical causes. The most encountered preanalytical rejection reasons were improper test request, inadequate sample volume, and incomplete/incorrect information in the test request. The biochemistry samples had the highest rejection rates in the main, cardiovascular, oncology, obstetrics & gynecology, and physical therapy & rehabilitation departments. The coagulation samples were mostly rejected in the neurology and orthopedics departments, and the hemogram samples had the highest rejection rates in the pediatrics department.Conclusions: The preanalytical phase of the total testing procedure is the stage most vulnerable to errors. Therefore, it is crucial to focus on identifying preanalytical errors and implementing corrective actions, as this will enhance the accuracy and quality of the test results.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 9","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0